Atea Pharmaceuticals (AVIR) Stock Price, News & Analysis

Company Overview

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing oral antiviral medicines for serious viral diseases. Its research centers on compounds intended to interfere with viral replication.

The company’s investigational portfolio has included bemnifosbuvir, an oral antiviral candidate studied for COVID-19, as well as programs targeting other viral infections, including dengue. These medicines are investigational and are not established marketed treatments.

Based in Boston, Massachusetts, Atea conducts research and clinical development and has evaluated its candidates in studies involving participants across multiple regions. The company is led by founder and Chief Executive Officer Jean-Pierre Sommadossi.

Key Stats

• Today's Range: $4.10 to $4.36
• 50-Day Range: $4.04 to $5.83
• 52-Week Range: $2.89 to $6.45
• Volume: 302,652 shs
• Average Volume: 305,583 shs
• Market Capitalization: $345.29 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Hold

Atea Pharmaceuticals Stock Analysis - MarketRank™

Atea Pharmaceuticals scored higher than 60% of companies evaluated by MarketBeat, and ranked 387th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Atea Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 strong buy rating, no buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Atea Pharmaceuticals has a consensus price target of $7.00, representing about 62.8% upside from its current price of $4.30.

Amount of Analyst Coverage

Atea Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Atea Pharmaceuticals are expected to grow in the coming year, from ($1.91) to ($1.40) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Atea Pharmaceuticals is -2.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Atea Pharmaceuticals is -2.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Atea Pharmaceuticals has a P/B Ratio of 1.96. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.78% of the float of Atea Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Atea Pharmaceuticals has a short interest ratio ("days to cover") of 9.55.

Change versus previous month

Short interest in Atea Pharmaceuticals has recently decreased by 2.02%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Atea Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Atea Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.77

News Sentiment

Atea Pharmaceuticals has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Atea Pharmaceuticals this week, compared to 2 articles on an average week.

MarketBeat Follows

1 people have added Atea Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Atea Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

21.60% of the stock of Atea Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

86.67% of the stock of Atea Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/09/2026
• Today: 11/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:AVIR
• CIK: 1593899
• Web: www.ateapharma.com
• Phone: 857-284-8891
• Fax: N/A
• Employees: 55
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Atea Pharmaceuticals: $7.00
• High Price Target: $7.00
• Low Price Target: $7.00
• Potential Upside/Downside: +62.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.95)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$158.35 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -69.91%
• Return on Assets: -61.22%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.00
• Quick Ratio: 8.13

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.19 per share
• Price / Book: 1.96

Miscellaneous

• Outstanding Shares: 80,300,000
• Free Float: 62,958,000
• Market Cap: $345.29 million
• Optionable: Optionable
• Beta: 0.76